Search
Hillhouse Capital Unloads HK$1.7 Billion in Shares, Diluting Stake in GenScript Probio
2025-04-30 /
Read about 0 minute
Author：小编
GenScript Probio, a wholly-owned subsidiary of GenScript, has released an equity transfer announcement revealing that Hillhouse Capital has divested its 13.37% stake in Probio Cayman to a GenScript subsidiary for a sum of US$225.1 million. Consequently, GenScript's holding in Probio Cayman has surged to 85.09%. As a prominent CDMO service provider, Probio Cayman has inked a PD-1 VHH antibody licensing agreement with Innovent Biologics and anticipates receiving financial inflows from its partnership with Merck & Co. The Board of Directors at GenScript expresses optimism about the company's future growth prospects and potential synergies.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
